Rayan Braïk

Rayan Braïk

Auto-generated profile, based on publicly available information

Rayan Braïk

Service de Réanimation Chirurgicale Polyvalente, Department of Anaesthesiology and Critical Care, Sorbonne University, GRC 29, AP-HP, DMU DREAM, Pitié-Salpêtrière Hospital, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
PBPierre-Louis Blot
Pierre-Louis Blot
MRMaxime Renaux
Maxime Renaux
TATimothée Ayasse
Timothée Ayasse
LCLucie Collet
Lucie Collet
AJArthur James
Arthur James
RBRayan Braïk
Rayan Braïk

1 January 2026 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ASAlice Soumare
Alice Soumare
TKThomas Kapfer
Thomas Kapfer
TBThomas Botrel
Thomas Botrel
LALeslie Adda
Leslie Adda
MRMaxime Renaux
Maxime Renaux
RBRayan Braïk
Rayan Braïk
The benefit-risk profile of systemic corticosteroids in non-COVID-19 pneumonia and acute respiratory distress syndrome (ARDS) remains debated. To assess corticosteroid effects on mortality and infection-related complications in adults with severe pneumonia or ARDS. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform through September 2025. Randomized controlled trials comparing systemic corticosteroids with placebo and usual care. Primary analysis: severe pneumonia or ARDS with corticosteroids 3 mg/kg-1 of body weight per day-1 or less (prednisone-equivalent) for 15 days or less, initiated within 7 days. Paired reviewers; consensus for disagreements. From 16 831 screened records, 20 studies (15 severe pneumonia, 5 ARDS) including 3459 participants met criteria. Low-dose, short-course corticosteroids probably reduce short-term mortality in severe pneumonia (15 studies, 2445 participants; risk ratio [RR], 0.73 [95% CI, 0.57 to 0.93]; I 2 = 14%; moderate certainty) and ARDS (5 studies, 1014 participants; RR, 0.77 [CI, 0.61 to 0.99]; I 2 = 23%; moderate certainty). Corticosteroids may reduce secondary shock in severe pneumonia (9 studies, 1690 participants; RR, 0.49 [CI, 0.26 to 0.92]; I 2 = 55%; low certainty). They probably result in little to no difference in hospital-acquired infections (severe pneumonia: 7 studies, 1665 participants; RR, 0.99 [CI, 0.82 to 1.20]; I 2 = 0%; moderate certainty; ARDS: 4 studies, 677 participants; RR, 0.97 [CI, 0.59 to 1.59]; I 2 = 0%; low certainty) or secondary pneumonia (severe pneumonia: 4 studies, 1011 participants; RR, 0.96 [CI, 0.66 to 1.39]; I 2 = 0%; ARDS: 4 studies, 677 participants; RR, 0.88 [CI, 0.43 to 1.79]; I 2 = 0%; both low certainty). Evidence is very uncertain for catheter-related and bloodstream infections. Long-term mortality evidence is very uncertain for severe pneumonia. Heterogeneous pneumonia severity classification limiting subgroup precision. In severe pneumonia and ARDS, adjunct corticosteroids probably reduce short-term mortality. In severe pneumonia, they may reduce secondary shock. In both conditions, corticosteroids may have little or no effect on hospital-acquired infections. None. (PROSPERO: CRD42024536301).

14 February 2025 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Open access
RBRayan Braïk
Rayan Braïk
This review reconsiders the classification of corticosteroids as immunosuppressants in the management of acute inflammatory conditions in critical care. Despite their widespread use in ARDS and septic shock, the association between corticosteroid therapy and increased infection risk remains contentious. By exploring alternative mechanisms and presenting new hypotheses, this review suggests that the traditional view of corticosteroids as immunosuppressants may be overly simplistic and context dependent.

28 September 2024 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
RBRayan Braïk
Rayan Braïk
SJSafa Jebali
Safa Jebali
PBPierre-Louis Blot
Pierre-Louis Blot
JEJulia Egbeola
Julia Egbeola
AJArthur James
Arthur James
JCJean-Michel Constantin
Jean-Michel Constantin
The transfusion strategy in the acute phase of myocardial infarction (AMI) remains a debated topic with non-standardized guidelines. This study aimed to evaluate the impact of liberal versus restrictive transfusion strategies on mortality during AMI. A systematic search was conducted across MEDLINE, EMBASE, and the COCHRANE library databases, focusing on randomized controlled trials (RCTs). The primary endpoint was the latest measured mortality within 90 days following myocardial infarction (MI). Secondary endpoints included recurrence of MI, cardiovascular mortality, stroke occurrence, unplanned revascularization, and a composite endpoint of death or recurrent MI. Mixed and random-effects models were employed to estimate relative risks. Sensitivity analyses were conducted using two approaches: one incorporating only studies assessed as low risk of bias according to the Rob2 tool, and another employing a Bayesian analysis. Four RCTs including a total of 4324 participants were analyzed. Neither the fixed-effect nor random-effects models demonstrated a significant reduction in mortality, with risk ratios (RR) of 1.16 (95% CI 0.95–1.40) for the fixed-effect model and 1.13 (95% CI 0.67–1.91) for the random-effects model (GRADE: low certainty of evidence). Sensitivity analyses, including the exclusion of two high-risk-of-bias studies and a Bayesian analysis, were consistent with the primary analysis. For the composite outcome death or MI both fixed-effect and random-effects models showed a statistically significant RR of 1.18 (95% CI 1.01–1.37) with negligible heterogeneity (I2 = 0%, p = 0.46), indicating results unfavorable to restrictive transfusion (GRADE: very low certainty of evidence). However, this result was primarily driven by a single study. For cardiac mortality, the fixed-effects model indicated a significant RR of 1.42 (95% CI 1.07–1.88), whereas the random-effects model showed non-significant RR of 1.05 (95% CI 0.36–3.80). Analyses of other secondary endpoints did not show statistically significant results. Our analysis did not demonstrate a significant benefit in early mortality with a liberal transfusion strategy compared to a restrictive strategy for AMI, low certainty of evidence. Liberal transfusion may reduce the risk of the composite outcome death or MI, with very low certainty of evidence. These findings should be interpreted with caution in critically ill patients.

1 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRaphael Cohen
Raphael Cohen
VDVincent Duval
Vincent Duval
RARida Al-Rifai
Rida Al-Rifai
SMSidrah Maryam
Sidrah Maryam
ISIcia Santos-Zas
Icia Santos-Zas
HOHafid Ait Oufella
Hafid Ait Oufella
Ischemic heart failure remains a major clinical challenge, underscoring the need to better understand post-infarction immune mechanisms and identify new therapeutic targets. Both innate and adaptive immunity contribute to adverse cardiac remodeling following myocardial infarction (MI), yet the role of cytotoxic cells such as natural killer (NK) cells remains poorly defined. Here, we show that after acute MI in mice, NK cells are recruited to the ischemic myocardium in a CCR2-dependent manner and become activated. Activated NK cells locally release granzyme B, promoting cardiomyocyte apoptosis, adverse ventricular remodeling, and impaired cardiac function. Genetic deletion or pharmacological depletion of NK cells reduces cardiomyocyte death, attenuates inflammation, limits myocardial injury, and improves cardiac function. In contrast, NK cell activation using an anti-NKG2A monoclonal antibody exacerbates ischemic heart failure. We further demonstrate that NK cells regulate bone marrow myelopoiesis through local GM-CSF production. Finally, we identify a distinct NK cellular and transcriptomic signature in human ischemic heart tissue at early stages. Together, these findings reveal a detrimental role for NK cells following acute MI and highlight NK cells as potential therapeutic targets to limit adverse cardiac remodeling.

26 September 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RBRayan Braïk
Rayan Braïk
PBPascal Berna
Pascal Berna
JWJustine Walbecq
Justine Walbecq
YGYohan Germain
Yohan Germain
TFThomas Flet
Thomas Flet
OAOsama Abou-Arab
Osama Abou-Arab
The optimal tidal volume (TV) during one-lung ventilation (OLV) for thoracic surgery remains uncertain. This study aimed to evaluate the association between intraoperative tidal volume and the incidence of postoperative respiratory complications in patients undergoing thoracic surgery. We conducted a post-hoc analysis of single-center observational cohort study who underwent elective thoracic surgery with OLV between January 2015 and January 2021. Patients were categorized according to their mean intraoperative TV: < 5 mL/kg versus ≥ 5 mL/kg predicted body weight (PBW). The primary outcome was postoperative respiratory complications (PRCs) within 7 days. Secondary outcomes included other major complications and 30-/90-day mortality. Analyses were adjusted using propensity score overlap weighting. Sensitivity analyses included an alternative 6 mL/kg threshold and stratified analyses by TV range. A post hoc Bayesian analysis was also performed. We included 1,234 patients. PRCs occurred in 37/458 (8.1%) patients in the < 5 mL/kg group and 45/776 (5.8%) in the ≥ 5 mL/kg group. After adjustment, TV < 5 mL/kg was not associated with a reduced risk of PRCs (RR, 1.07; 95% CI, 0.69–1.66). Using a 6 mL/kg threshold yielded similar findings (RR, 0.93; 95% CI, 0.47–1.82). Stratified analyses by tidal volume range (> 4, 4–5, 5–6, and > 6 mL/kg) showed no significant association between tidal volume and PRCs. However, TV < 5 mL/kg was associated with an increased risk of postoperative atrial fibrillation (RR, 1.50; 95% CI, 1.09–2.05). Bayesian analyses showed no evidence of a beneficial effect of TV < 5 mL/kg on the composite outcome of postoperative complications, even when using favorable prior assumptions. In this cohort, tidal volumes < 5 mL/kg during OLV were not associated with a lower incidence of postoperative respiratory complications